Erlocip 150 mg Tablet

Erlocip 150mg tablet is a medication that is a tyrosine kinase inhibitor, prescribed for metastatic non-small cell cancer of the lung, and pancreatic cancer. Erlocip has been shown a benefit of survival in the treatment of lung cancer in III trials. Erlocip tablets also has been approved for treating locally metastatic or advanced non-small cell cancer of the lungs that has failed at least one chemotherapy regimen previous.
A test for the EGFR mutation in patients with cancer has been developed. Generic Erlocip may predict who will respond to this medication and other tyrosine kinase inhibitors. Responses among females who were never smokers have had the best effect, particularly Asian women and those with adenocarcinoma cell type. Erlocip inhibits the intracellular phosphorylation of tyrosine kinasa associated with the epidermal growth factor receptor is expressed on the surface of the cell of normal as well as cancer cells.

The medication is show to interact with other drugs such as atazanavir, erythromycin, clarithromycin, indinavir (Sulphate), ketoconazole, nelfinavir, rifabutin, ritonavir, rifampicin, St.John?s wort extract, troleandomycin, telithromycin. Always consult your physician for any change of dose regiment or an alternative choice of drug that may strictly be required.

Fatigue, nausea, vomiting, diarrhea, anorexia, dyspnea, rashes, abdominal pain, pruritus, stomatitis, dyspepsia, dry skin, cough, conjunctivitis, infection, keratoconjunctivitis sicca.